Search

Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity. A third cohort is ongoing following FDA’s OPTIMUS

Meet Paralab Bio, our new member. We talked to its Andrea Zapater, Bio Product Specialist.

Private funding raised by the sector reached an all-time high, surpassing 228 million euros after a 37% increase.

The European Commission thus reinforces biotechnology as central to Europe's green, digital and long-term industrial transition.

Geneis Biomed interviews Dr. Rafael Simón, head of the Endocrinology and Nutrition Department at Vall d'Hebron University Hospital and Director of the Diabetes and Metabolism Research Unit at Vall d

Biotechnology addresses environmental challenges through bioremediation, the production of renewable energy, sustainable agriculture, or the reduction of greenhouse gas emissions.

Pharmaron is holding a training webinar on June 20 on the importance of oligonucleotide drugs in modern medicine.

Among the most important emerging technologies are the manipulation of the microbiota, CAR-T cell therapies, and gene editing using CRISPR-Cas9, techniques that are positioning Spain as a benchmark in

The award recognizes the success of companies less than 10 years old that create wealth and employment in the Basque Country community.

The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML). The combination showed substantial

BIO International Convention 2024. Congreso de la European Hematology Association (EHA) 2024. European Network to Cure ALS (ENCALS) 2024.

BCN HEALTH desarrolló un modelo de costes aplicable a nivel mundial para la atención de la talasemia.

Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia, and Spain . Oryzon to validate epigenetic agents by applying a personalized